Midiana (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Midiana, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial development in women of reproductive age.

GNH USA supplies Midiana as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Midiana, a combined oral contraceptive, is indicated for hormonal contraception in women.

- Prevention of pregnancy: provides reliable contraceptive protection when taken as directed. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns. - Treatment of moderate acne: can improve acne associated with hormonal fluctuations.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: discomfort or swelling of the breasts. - Headache: occasional tension‑type headaches. - Weight gain: slight increase in body weight. - Mood changes: irritability or mood swings. - Spotting: irregular breakthrough bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Arterial thrombosis: stroke or myocardial infarction. - Hypertension: new‑onset or worsening high blood pressure. - Liver disorders: cholestatic jaundice or hepatic dysfunction. - Gallbladder disease: gallstones or cholecystitis. - Severe allergic reactions: anaphylaxis, angioedema, or skin rash.

Midiana should be used with caution in the following situations: - Pregnancy: contraindicated; avoid use during pregnancy. - Smoking: especially >15 cigarettes/day in women >35 years. - History of thromboembolism: increased risk of clot formation. - Liver disease: impaired metabolism may alter drug levels. - Hypertension: monitor blood pressure regularly. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Midiana may interact with several medicines that affect its efficacy or safety.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that reduces contraceptive effectiveness. - Carbamazepine: enzyme inducer that may lead to contraceptive failure. - Phenytoin: reduces plasma levels of hormonal components. - St. John's wort: herbal inducer that can diminish contraceptive protection.

Moderate Interactions (Monitor Closely): - Ketoconazole: CYP3A4 inhibitor that may increase hormone concentrations. - Erythromycin: macrolide antibiotic that can raise ethinylestradiol levels. - Fluoxetine: SSRI that may slightly elevate hormone exposure. - NSAIDs: may increase risk of hypertension when used long‑term.